obese patients with type 2 diabetes mellitus
Conditions
Interventions
placebo group:placebo
100ug Group:Losenatide 100ug
200ug Group:Losenatide 200ug
300ug Group:Losenatide 300ug
orlistat group:orlistat
Sponsors
The Second XIANGYA Hospital Of Central South University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Volunteer to participate in this clinical study and sign informed consent; 2. Aged from 18 to 70 years old; 3. BMI >=28 kg/m2; 4. The body weight was kept constant for 3 months, and the weight change was less than 5%; 5. After diagnosis, no hypoglycemic drugs were used, or oral administration of hypoglycemic drugs except DPP-4 inhibitor was given after diagnosis, and the treatment dose was stable for 3 months; 6. HbA1c >=7%.
Exclusion criteria
Exclusion criteria: 1. They took weight loss drugs or participated in weight loss study within 3 months before enrollment; 2. Infection and other stress state; 3. Weight loss surgery was performed in the past; 4. Endocrine diseases such as type 1 diabetes, special type diabetes, hypothyroidism, Cushing's syndrome, polycystic ovary syndrome, etc; 5. In the past three months, they have taken drugs known to affect weight or appetite, such as weight loss drugs, corticosteroids, antidepressants, diazepam, nonselective systemic antihistamines, nicotine substitutes, DPP-4 inhibitors, insulin or two or more hypoglycemic drugs; 6. Combined with hyperlipidemia (TG) ? 5.7 mmol/L; 7. He suffered from serious diseases such as cardio cerebrovascular, liver, kidney and hematopoietic system; 8. He suffered from neoplastic diseases, including medullary thyroid carcinoma and multiple endocrine tumor syndrome; 9. Have had or are suffering from pancreatitis; 10. Chronic gastrointestinal disease or malabsorption syndrome; 11. Pregnancy, lactation and nearly 4 months of gestation; 12. Have mental illness and family history; 13. Alcohol addiction or intellectual (cognitive) disorders; 14. Those who can not complete subcutaneous injection by themselves and can not get proper help.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analysis of human body composition;quality of life;Drug compliance;blood sugar;BMI; | — |
Countries
China
Contacts
Public ContactShiping Liu
Endocrinology and Metabolism department, The Second XIANGYA Hospital Of Central South University
Outcome results
None listed